(Q35817265)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

0 references

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Hidehito Horinouchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Noboru Yamamoto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ikuo Sekine

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Hiroshi Nokihara

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Kaoru Kubota

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Shintaro Kanda

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Shigehiro Yagishita

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Hiroshi Wakui

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Satoru Kitazono

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Hidenori Mizugaki

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Takuto Tokudome

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tomohide Tamura

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

1 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

881-889

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

7 March 2020

copyright license

start time

1 May 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10637-015-0243-5

0 references

cites work

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products f

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Hepatotoxicity of chemotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Evolution of end points for cancer immunotherapy trials.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

Phase I/II study of ipilimumab for patients with metastatic melanoma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4491360

10.1007/S10637-015-0243-5

24 September 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

25924991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25924991%20AND%20SRC:MED&resulttype=core&format=json